Yes, topiramate is used off-label for binge eating disorder
Topiramate is commonly prescribed off-label for binge eating disorder (BED) and has demonstrated efficacy in reducing binge episodes and promoting weight loss, though it is not FDA-approved for this indication. 1
Evidence Supporting Off-Label Use
Guideline Recognition
The 2022 AGA Clinical Practice Guideline explicitly acknowledges that "topiramate has been used to manage some eating disorders, although most published effects are case series or case reports" 1. The 2016 AACE/ACE guidelines provide more specific direction, stating that "in patients with overweight or obesity and binge eating disorder, treatment with orlistat or approved medications containing topiramate or bupropion may be considered in conjunction with structured lifestyle therapy, cognitive behavioral therapy, and/or other psychological interventions" 2.
The 2023 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines give topiramate a Level of Evidence A and Grade of Recommendation 1 for BED treatment 3, which represents the highest level of recommendation based on strong evidence.
Clinical Trial Evidence
Multiple randomized controlled trials support topiramate's efficacy in BED:
A large multicenter trial of 407 patients demonstrated that topiramate reduced binge eating days/week by 3.5 versus 2.5 with placebo, achieved 58% remission rates (versus 29% placebo), and produced significant weight loss of 4.5 kg 4
Meta-analysis of 528 BED patients showed topiramate significantly reduced binge episodes per week (MD = -1.31), binge days per week (MD = -0.98), and weight (MD = -4.91 kg) compared to placebo 5
Practical Considerations
Dosing Approach
While specific BED dosing protocols vary across studies, the general approach mirrors obesity treatment: start low at 25-50 mg/day and titrate slowly by 25-50 mg increments weekly or biweekly to target doses of 200-400 mg/day 6. One pharmacokinetic study identified 125 mg daily as the minimum dose needed for marked reduction in binge eating frequency 7.
Safety Profile and Limitations
The major limitation is tolerability. Discontinuation rates due to adverse events are approximately 16% with topiramate versus 8% with placebo 4. Common side effects include paresthesias, cognitive changes, somnolence, and nausea 2. Patients withdrew significantly more frequently for safety reasons compared to placebo (RR = 1.90) 5.
Critical contraindications include:
- Glaucoma (topiramate should be avoided) 2
- Pregnancy (teratogenic risk of oral clefts requires effective contraception and pregnancy monitoring) 8
- History of kidney stones
- Metabolic acidosis risk requiring monitoring of electrolytes and creatinine 8
Treatment Algorithm
Screen for BED in patients with overweight/obesity being considered for weight-loss therapy 2
First-line approach: Structured behavioral/lifestyle program with cognitive behavioral therapy 2
Consider topiramate when:
- Psychotherapy alone is insufficient
- Patient has comorbid obesity (BMI ≥30 or ≥27 with complications)
- No contraindications present
- Used in conjunction with ongoing behavioral therapy 2
Alternative pharmacotherapy: The 2023 APA guidelines suggest lisdexamfetamine (the only FDA-approved medication for BED) or antidepressants as alternatives 9. Recent evidence also suggests GLP-1 agonists like semaglutide may be effective 10.
Important Caveats
Despite strong evidence, topiramate has not received marketing authorization for BED from any medicine regulatory agency 3. The evidence base consists primarily of trials lasting less than 12 months 1. The 2023 APA guidelines notably do not include topiramate in their formal recommendations, suggesting only lisdexamfetamine or antidepressants for BED patients who prefer medication or have not responded to psychotherapy 9.
Topiramate should always be combined with structured lifestyle therapy and psychological interventions, never used as monotherapy 2. Abrupt discontinuation must be avoided due to seizure risk; taper by taking one capsule every other day for at least one week before stopping 1.